

# Mitesh J Borad

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8473936/publications.pdf>

Version: 2024-02-01

158  
papers

12,798  
citations

61687

45  
h-index

30277

107  
g-index

193  
all docs

193  
docs citations

193  
times ranked

15771  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2009, 361, 1164-1172.	13.9	1,054
2	Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 671-684.	5.1	923
3	Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 180-188.	1.2	647
4	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 796-807.	5.1	620
5	Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers. <i>Journal of Clinical Oncology</i> , 2010, 28, 4877-4883.	0.8	552
6	Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 276-282.	0.8	524
7	Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 2502-2511.	3.2	499
8	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 541-565.	2.3	477
9	Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2020, 122, 1630-1637.	2.9	472
10	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. <i>Cell Reports</i> , 2017, 18, 2780-2794.	2.9	416
11	Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers. <i>JAMA Oncology</i> , 2019, 5, 824.	3.4	335
12	The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. <i>Clinical Cancer Research</i> , 2003, 9, 1136-44.	3.2	312
13	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	15.2	297
14	Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma. <i>PLoS Genetics</i> , 2014, 10, e1004135.	1.5	292
15	Hepatocytes direct the formation of a pro-metastatic niche in the liver. <i>Nature</i> , 2019, 567, 249-252.	13.7	263
16	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	0.8	257
17	Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2014, 45, 1630-1638.	1.1	235
18	Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 803-815.	3.7	205

#	ARTICLE	IF	CITATIONS
19	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With <i>IDH1</i> Mutation. <i>JAMA Oncology</i> , 2021, 7, 1669.	3.4	194
20	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. <i>Lancet Oncology</i> , The, 2021, 22, 1290-1300.	5.1	178
21	Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1475-1481.	0.8	152
22	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4073-4073.	0.8	133
23	Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 2997-3004.	3.2	132
24	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	3.4	124
25	IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6 sensitive mechanism. <i>Hepatology</i> , 2015, 61, 1627-1642.	3.6	115
26	ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome. <i>Science Advances</i> , 2021, 7, eabl8213.	4.7	112
27	Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 1054-1062.	0.6	110
28	Cholangiocarcinoma: Molecular Pathways and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2014, 34, 456-464.	1.8	106
29	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with <i>FGFR2</i> rearrangements. <i>Future Oncology</i> , 2020, 16, 2385-2399.	1.1	96
30	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
31	Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2018, 67, 2338-2351.	3.6	92
32	Cholangiocarcinoma With <i>FGFR</i> Genetic Aberrations: A Unique Clinical Phenotype. <i>JCO Precision Oncology</i> , 2018, 2, 1-12.	1.5	86
33	Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 439-447.	1.9	85
34	Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 1092-1100.	3.2	78
35	Second-line therapies in advanced biliary tract cancers. <i>Lancet Oncology</i> , The, 2020, 21, e29-e41.	5.1	77
36	Immunotherapy in pancreatic cancer treatment: a new frontier. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 168-194.	1.4	73

#	ARTICLE	IF	CITATIONS
37	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. <i>Cancer Letters</i> , 2016, 380, 163-173.	3.2	72
38	The Role of Maintenance Strategies in Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, e194489.	3.4	65
39	Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1432-1438.	0.5	63
40	FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice. <i>Cancers</i> , 2021, 13, 2968.	1.7	63
41	Safety Studies on Intrahepatic or Intratumoral Injection of Oncolytic Vesicular Stomatitis Virus Expressing Interferon- $\beta$ in Rodents and Nonhuman Primates. <i>Human Gene Therapy</i> , 2010, 21, 451-462.	1.4	62
42	Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017, 8, 27145-27154.	0.8	55
43	Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 118, 153-161.	2.9	51
44	A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2013, 19, 268-278.	3.2	48
45	Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature. <i>Yale Journal of Biology and Medicine</i> , 2009, 82, 1-6.	0.2	46
46	Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 710-716.	1.2	44
47	Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 264-268.	1.0	44
48	Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. <i>Journal of Clinical Oncology</i> , 2021, 39, 266-266.	0.8	41
49	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1002-1009.	3.2	39
50	Adjuvant systemic therapy after resection of node positive gallbladder cancer: Time for a well-designed trial? (Results of a US-national retrospective cohort study). <i>International Journal of Surgery</i> , 2018, 52, 171-179.	1.1	38
51	Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. <i>Translational Oncology</i> , 2019, 12, 143-153.	1.7	37
52	Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular clinical analysis and potential targeted approach. <i>Hepatology International</i> , 2019, 13, 490-500.	1.9	36
53	Genomic and Epigenomic Landscaping Defines New Therapeutic Targets for Adenosquamous Carcinoma of the Pancreas. <i>Cancer Research</i> , 2020, 80, 4324-4334.	0.4	36
54	Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e508-e528.	2.4	36

#	ARTICLE	IF	CITATIONS
55	Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. <i>JCO Precision Oncology</i> , 2020, 4, 557-569.	1.5	35
56	FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma. <i>Journal of Hepatology</i> , 2021, 75, 351-362.	1.8	35
57	Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 604-614.	0.7	34
58	Placental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma. <i>Gut</i> , 2022, 71, 185-193.	6.1	34
59	A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (<i>FGFR2</i>) gene rearrangements (FOENIX-CCA3).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS600-TPS600.	0.8	34
60	Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers. <i>Scientific Reports</i> , 2016, 6, 25.	1.6	32
61	Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 39-49.	6.0	32
62	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. <i>Oncolytic Virotherapy</i> , 2017, Volume 6, 11-18.	6.0	32
63	Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2012, 30, 2334-2343.	1.2	31
64	Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 554-561.	0.6	31
65	A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 684-692.	1.2	30
66	Phase I Studies of CBP501, a G2 Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 3431-3442.	3.2	29
67	Secondâ€line treatment in patients with pancreatic ductal adenocarcinoma: A metaâ€analysis. <i>Cancer</i> , 2017, 123, 4680-4686.	2.0	29
68	Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 931-941.	1.1	28
69	Emerging role of precision medicine in biliary tract cancers. <i>Npj Precision Oncology</i> , 2018, 2, 21.	2.3	27
70	HSP90 Inhibition Drives Degradation of FGFR2 Fusion Proteins: Implications for Treatment of Cholangiocarcinoma. <i>Hepatology</i> , 2019, 69, 131-142.	3.6	27
71	The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 789-796.	0.6	26
72	Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). <i>Targeted Oncology</i> , 2017, 12, 201-209.	1.7	25

#	ARTICLE	IF	CITATIONS
73	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. <i>Cancers</i> , 2022, 14, 2056.	1.7	24
74	Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With Cancer. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1583-1591.	1.4	23
75	Portal Vein Embolization: Impact of Chemotherapy and Genetic Mutations. <i>Journal of Clinical Medicine</i> , 2017, 6, 26.	1.0	23
76	Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma. <i>Oncologist</i> , 2021, 26, 569-578.	1.9	23
77	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. <i>Future Oncology</i> , 2018, 14, 553-566.	1.1	22
78	E6201, an intravenous MEK1 inhibitor, achieves an exceptional response in BRAF V600E-mutated metastatic malignant melanoma with brain metastases. <i>Investigational New Drugs</i> , 2019, 37, 636-645.	1.2	22
79	A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.	1.2	21
80	Oncolytic viruses: perspectives on clinical development. <i>Current Opinion in Virology</i> , 2015, 13, 55-60.	2.6	19
81	Phase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphoma. <i>International Journal of Clinical Oncology</i> , 2013, 18, 934-941.	1.0	17
82	Feasibility of circulating tumor DNA testing in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 745-750.	0.6	17
83	Phase 1 trial of Vismodegib and Erlotinib combination in metastatic pancreatic cancer. <i>Pancreatology</i> , 2020, 20, 101-109.	0.5	17
84	Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00414.	1.3	17
85	Prevalent hepatitis B surface antigen among first-time blood donors in Gabon. <i>PLoS ONE</i> , 2018, 13, e0194285.	1.1	16
86	Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study. <i>British Journal of Cancer</i> , 2018, 118, 1580-1585.	2.9	16
87	Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice. <i>JCO Precision Oncology</i> , 2021, 5, 432-441.	1.5	16
88	The Impact of Concomitant Medication Use on Patient Eligibility for Phase I Cancer Clinical Trials. <i>Journal of Cancer</i> , 2012, 3, 345-353.	1.2	15
89	Genomic Medicine and Incidental Findings: Balancing Actionability and Patient Autonomy. <i>Mayo Clinic Proceedings</i> , 2014, 89, 718-721.	1.4	15
90	Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review. <i>Case Reports in Gastroenterology</i> , 2017, 10, 605-612.	0.3	15

#	ARTICLE	IF	CITATIONS
91	Neutrophil to lymphocyte ratio as a prognostic marker in metastatic gallbladder cancer. <i>Hpb</i> , 2020, 22, 1490-1495.	0.1	15
92	Novel staging system using carbohydrate antigen (CA) 19-9 in extra-hepatic cholangiocarcinoma and its implications on overall survival. <i>European Journal of Surgical Oncology</i> , 2020, 46, 789-795.	0.5	15
93	Whole Genome Analyses of a Well-Differentiated Liposarcoma Reveals Novel SYT1 and DDR2 Rearrangements. <i>PLoS ONE</i> , 2014, 9, e87113.	1.1	14
94	Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 1063-1078.	1.1	14
95	FIGHT-302: Phase III study of first-line (1L) pemigatinib (PEM) versus gemcitabine (GEM) plus cisplatin (CIS) for cholangiocarcinoma (CCA) with <i>FGFR2</i> fusions or rearrangements.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS592-TPS592.	0.8	14
96	Marantic Endocarditis Associated with Pancreatic Cancer: A Case Series. <i>Case Reports in Gastroenterology</i> , 2009, 3, 67-71.	0.3	13
97	Chromoanasythesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples. <i>BMC Cancer</i> , 2018, 18, 738.	1.1	13
98	Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. <i>Genome Biology</i> , 2021, 22, 227.	3.8	13
99	Targeting of the Hedgehog/GLI and mTOR pathways in advanced pancreatic cancer, a phase 1 trial of Vismodegib and Sirolimus combination. <i>Pancreatology</i> , 2020, 20, 1115-1122.	0.5	12
100	Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 125-131.	1.9	12
101	Oncolytic virotherapy in upper gastrointestinal tract cancers. <i>Oncolytic Virotherapy</i> , 2017, Volume 7, 13-24.	6.0	11
102	Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2019, 21, 379-386.	0.1	11
103	Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. <i>JCO Precision Oncology</i> , 2021, 5, 733-743.	1.5	11
104	Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, , .	0.5	11
105	Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .	1.5	11
106	Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer. <i>Diagnostics</i> , 2017, 7, 50.	1.3	10
107	MetaMarker: a pipeline for <i>de novo</i> discovery of novel metagenomic biomarkers. <i>Bioinformatics</i> , 2019, 35, 3812-3814.	1.8	10
108	Phase II Trial of Trifluridine/Tipiracil in Patients with Advanced, Refractory Biliary Tract Carcinoma. <i>Oncologist</i> , 2020, 25, 380-e763.	1.9	10

#	ARTICLE	IF	CITATIONS
109	Advances in the treatment of biliary tract cancers. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 1.	1.0	10
110	Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?. <i>Seminars in Liver Disease</i> , 2021, 41, 136-141.	1.8	10
111	Tumor-Treating Fields: A fourth modality in cancer treatment, new practice updates. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 168, 103535.	2.0	10
112	Isocitrate Dehydrogenase-Related Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes. <i>JCO Precision Oncology</i> , 2022, 6, e2100156.	1.5	10
113	Exploring the role of oncolytic viruses in hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 971-986.	1.0	9
114	Characteristics of Patients With Chronic Hepatitis B Virus Infection With Genotype E Predominance in Burkina Faso. <i>Hepatology Communications</i> , 2020, 4, 1781-1792.	2.0	9
115	Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 546-555.	2.0	9
116	Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study. <i>Cancer Prevention Research</i> , 2022, 15, 121-128.	0.7	9
117	A Phase I Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Topotecan at 4 mg/m <sup>2</sup> Administered Weekly as a 30-minute Intravenous Infusion in Patients With Cancer. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 268-275.	1.0	8
118	Oncolytic Adenoviruses in Gastrointestinal Cancers. <i>Biomedicines</i> , 2018, 6, 33.	1.4	8
119	Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma. <i>Chinese Clinical Oncology</i> , 2021, 10, 11-11.	0.4	8
120	Preoperative chemoradiation and IOERT for unresectable or borderline resectable pancreas cancer. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 352-60.	0.6	8
121	Circulating Cell-Free Tumor DNA in Advanced Pancreatic Adenocarcinoma Identifies Patients With Worse Overall Survival. <i>Frontiers in Oncology</i> , 2021, 11, 794009.	1.3	8
122	Tilsetolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1-13.	1.9	8
123	Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. <i>Nature Communications</i> , 2021, 12, 1930.	5.8	7
124	Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials. <i>Investigational New Drugs</i> , 2013, 31, 1056-1065.	1.2	6
125	Novel immunotherapy strategies for hepatobiliary cancers. <i>Immunotherapy</i> , 2018, 10, 1077-1091.	1.0	6
126	Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.	3.6	6



#	ARTICLE	IF	CITATIONS
127	Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies: a single-center experience. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 288-297.	0.6	6
128	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. <i>Future Oncology</i> , 2014, 10, 1255-1275.	1.1	5
129	Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy. <i>Mayo Clinic Proceedings</i> , 2020, 95, 306-318.	1.4	5
130	Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS462-TPS462.	0.8	5
131	Patient willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials. <i>Cancer</i> , 2011, 117, 3276-3283.	2.0	4
132	A Multicenter, Open-Label, Phase 1 Study Evaluating the Safety and Tolerability of Pegaspargase in Combination with Gemcitabine in Advanced Metastatic Solid Tumors and Lymphoma. <i>Cancer Investigation</i> , 2015, 33, 172-179.	0.6	4
133	Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma. <i>Anti-Cancer Drugs</i> , 2017, 28, 127-132.	0.7	4
134	Data from the third dose cohort of an ongoing study with ADP-A2AFP SPEAR T cells. <i>Journal of Hepatology</i> , 2020, 73, S122.	1.8	4
135	Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). <i>Investigational New Drugs</i> , 2021, 39, 1072-1080.	1.2	4
136	FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.	1.1	4
137	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. <i>JCO Precision Oncology</i> , 2022, , .	1.5	4
138	Comprehensive Genomic Analysis of Metastatic Mucinous Urethral Adenocarcinoma Guides Precision Oncology Treatment: Targetable EGFR Amplification Leading to Successful Treatment With Erlotinib. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e727-e734.	0.9	3
139	Quantitative Imaging System for Cancer Diagnosis and Treatment Planning: An Interdisciplinary Approach. , 2017, , 152-175.		3
140	Aspirin and Statin Use and the Risk of Gallbladder Cancer. <i>Cancers</i> , 2021, 13, 1186.	1.7	3
141	A multicenter phase 1/2 study investigating the safety, pharmacokinetics, pharmacodynamics and efficacy of a small molecule antimetabolite, RX-3117, plus nab-paclitaxel in pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 81-90.	1.2	3
142	Targeting hyaluronan (HA) in tumor stroma: Interim safety and translational evaluation of pegylated hyaluronidase (PEGPH20) in patients (pts) with advanced solid tumorsâ€”A focus on gastrointestinal malignancies.. <i>Journal of Clinical Oncology</i> , 2012, 30, 249-249.	0.8	3
143	Reply to M. Buyse et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e453-e453.	0.8	2
144	Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. <i>Investigational New Drugs</i> , 2016, 34, 96-103.	1.2	2

#	ARTICLE	IF	CITATIONS
145	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240.	1.5	2
146	P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer. <i>Annals of Oncology</i> , 2021, 32, S333.	0.6	2
147	Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 641044.	1.3	2
148	Hypoxia-Activated Alkylating Agents in BRCA1-Mutant Ovarian Serous Carcinoma. <i>Cureus</i> , 2017, 9, e1517.	0.2	2
149	Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 190-190.	0.8	2
150	Updated data from an ongoing study with ADP-A2AFP spear T-cells. <i>Journal of Hepatology</i> , 2020, 73, S910-S911.	1.8	1
151	Germline cancer susceptibility gene testing in unselected patients with colorectal adenocarcinoma: a multi-center prospective study. <i>Molecular Genetics and Metabolism</i> , 2021, 132, S34-S35.	0.5	1
152	Recent advances in understanding cholangiocarcinoma. <i>Faculty Reviews</i> , 2020, 9, 15.	1.7	1
153	Preclinical evaluation of LCK as a novel therapeutic target in YAP-activated and FGFR2-altered cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 463-463.	0.8	1
154	Phase I Study of Concomitant Pemetrexed and Cisplatin Plus External Beam Radiation Therapy in Patients with Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Carcinomas. <i>Cancer Investigation</i> , 2016, 34, 57-63.	0.6	0
155	2-O, 3-O Desulfated Heparin (ODSH) May Mitigate Chemotherapy-Induced Thrombocytopenia and Neutropenia in Patients Treated with Combination Gemcitabine (G)/Nab-Paclitaxel (A), a Myelosuppressive Chemotherapy Regimen. <i>Blood</i> , 2012, 120, 4723-4723.	0.6	0
156	Perspectives on immunotherapy utilization for hepatobiliary cancers in the United States. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 501-504.	0.7	0
157	Recent advances in understanding cholangiocarcinoma. <i>Faculty Reviews</i> , 2020, 9, 15.	1.7	0
158	Reply to A. Rizzo et al. <i>JCO Precision Oncology</i> , 2022, 6, e2200061.	1.5	0